SynthesisInternational journal of nanomedicine2020
The Size-dependent Cytotoxicity of Amorphous Silica Nanoparticles: A Systematic Review of in vitro Studies.
Synthesis in International journal of nanomedicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed.
- Unlocking the potential of mesoporous silica nanoparticles: balancing biomedical applications and safety concerns.Drug delivery · 2026Review
- Size-Dependent Metabolic Reprogramming in A549 Cells Induced by Mesoporous Silica Nanoparticles: Insights from Subcellular Targeting.Metabolites · 2026Article
- Assessment of cytotoxicity and genomic instability induced by coal-derived nanoparticles in V79 and HaCaT Cells.Archives of toxicology · 2026Article
- The Next Wave of Immunotherapy: A Critical Review of Nanotechnology Strategies for Immune Checkpoint Blockade.Pharmaceutics · 2026Review
- Batch-Dependent Hepatobiliary Toxicity of 10 nm Silver Nanoparticles After Single Intravenous Administration in Mice.Nanomaterials (Basel, Switzerland) · 2026Article
- Gestational Intranasal Exposure to Silicon Dioxide Nanoparticles in Rats.International journal of nanomedicine · 2026Article
- Tools of the trade: leveraging 3DFrontiers in pharmacology · 2026Review
- Nanocarriers for Psoriasis Treatment: Insights from a Clinical Trial Registered on the Global Clinical Trials Registry Platform.International journal of nanomedicine · 2026Review
- Combination of laser-generated silicon NPs and electrospun-nanofibres for the development of new-generation bioactive wound dressings.RSC advances · 2025Article
- Nanotoxicity of Porous Silica Nanoparticles: Physicochemical Properties and Mechanistic Cellular Endpoints.Nanomaterials (Basel, Switzerland) · 2025Review
- Synthesis and Evaluation of Powerful Antioxidant Dendrimers Derived from D-Mannitol and Syringaldehyde.International journal of molecular sciences · 2025Article
- Microwave-assisted synthesis of silica quantum dots: a novel approach for targeting PI3K/AKT signaling in breast cancer therapy.RSC advances · 2025Article
- New approach methodologies for in vitro toxicity screening of nanomaterial using a pulmonary three-dimensional floating extracellular matrix model.Journal of biological engineering · 2025Article
- Biogenic copper and copper oxide nanoparticles to combat multidrug-resistantBiotechnology reports (Amsterdam, Netherlands) · 2025Review
- ZnO Nanoparticle-Infused Vaterite Coatings: A Novel Approach for Antimicrobial Titanium Implant Surfaces.Journal of functional biomaterials · 2025Article
- Review
- Calcium Phosphate-Induced Injury in Kidney Tubular Cells-Supersaturated Solution vs Preformed Crystals.Journal of biochemical and molecular toxicology · 2025Article
- Nanomaterials and immune checkpoint inhibitors in cancer immunotherapy: the synergistic innovation prospects.Frontiers in immunology · 2025Review
- Nanomaterial-Enhanced Immunotherapy: Advancing T-Cell-Based Treatments for Bladder Cancer.International journal of nanomedicine · 2025Review
- Lyophilized Polyvinyl Alcohol and Chitosan Scaffolds Pre-Loaded with Silicon Dioxide Nanoparticles for Tissue Regeneration.Molecules (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the increasing production and application of engineered amorphous silica nanoparticles (aSiNPs), people have more opportunities to be exposed to aSiNPs. However, the knowledge of its adverse health effects and related mechanisms is still limited, compared with the well-studied crystalline micron-sized silica. Since small differences in the physical-chemical properties of nanoparticles could cause significant differences in the toxic effect, it is important to distinguish how these variations influence the outcoming toxicity. Notably, particle size, as one of the essential characterizations of aSiNPs, is relevant to its biological activities. Thus, the aim of this systematic review was to summarize the relationship between the particle size of aSiNPs and its adverse biological effects. In order to avoid the influence of complicated in vivo experimental conditions on the toxic outcome, only in vitro toxicity studies which reported on the cytotoxic effect of different sizes aSiNPs were included. After the systematic literature retrieval, selection, and quality assessment process, 76 eligible scientific papers were finally included in this review. There were 76% of the studies that concluded a size-dependent cytotoxicity of aSiNPs, in which smaller-sized aSiNPs possessed greater toxicity. However, this trend could be modified by certain influence factors, such as the synthetic method of aSiNPs, particle aggregation state in cell culture medium, toxicity endpoint detection method, and some other experimental conditions. The effects of these influence factors on the size-dependent cytotoxicity of aSiNPs were also discussed in detail in the present review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.